Price
No data yet.
Social Signal Score
Analyst Ratings
26 analystsRevenue
$344.90M+29404.07%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jan Moller Mikkelsen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,189
- Beta
- 0.37
- Country
- DK
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 8.78
Financials
Revenue
$344.90M+29404.1%Net Income
$210.40MEBITDA
$68.08MFree Cash Flow
$283.11MEPS (diluted)
$3.08Shares Outstanding (diluted)
68.32M+171.2%Operating Expenses
$249.17MCash & Debt
$811.92MReturn of Capital
$52.06MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $691.71M | $-219.03M | $-3.62 |
| 2024 | $363.64M | $-378.08M | $-6.53 |
| 2023 | $266.72M | $-481.45M | $-8.55 |
| 2022 | $51.17M | $-583.19M | $-10.40 |
| 2021 | $7.78M | $-383.58M | $-7.00 |
| 2020 | $6.95M | $-418.95M | $-8.28 |
| 2019 | $13.38M | $-218.02M | $-4.69 |
| 2018 | $10.58M | $-130.10M | $-3.17 |
| 2017 | $1.53M | $-123.90M | $-3.68 |
| 2016 | $4.61M | $-68.50M | $-2.58 |
| 2015 | $8.12M | $-32.92M | $-1.39 |
| 2014 | $13.98M | $-9.66M | $-0.57 |
| 2013 | $20.41M | $4.08M | $0.38 |
| 2012 | $15.58M | $1.25M | $0.12 |
Valuation
ASNDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-57.14%Social Signal Score
Mentions (7)
- Newsseekingalpha.com·20d ago·Positive
Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases - All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
Ascendis Announces Planned $400 Million Share Repurchase Program COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company's ordinary shares (the Share Repurchase Program).
View source ↗ - Newsglobenewswire.com·29d ago·Neutral
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivot…
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
Ascendis Pharma A/S Q2 Earnings Call Highlights Ascendis Pharma A/S NASDAQ: ASND reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial TransCon-based therapies continued to increase.
View source ↗ - Newsglobenewswire.com·54d ago·Positive
Ascendis Pharma Reports Second Quarter 2026 Financial Results – Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH ® , €55 million for SKYTROFA ® , and €8 million for YUVIWEL ®
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $1.13 per share
Typical surprise +34.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$3.29 vs $1.71beat
- Thu, May 7$0.32 vs $0.19beat
- Wed, Feb 11$-0.64 vs $-0.06miss
- Wed, Nov 12$-1.17 vs $-0.41miss
- Thu, Aug 7$-0.93 vs $-1.42beat
- Thu, May 1$-1.66 vs $-1.56miss
Estimates and results for ASND via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ASND officers and directors.
- Bought
- $777k
- Sold
- $5.5m
9 trades
3 trades
- Bodenhoff Madssold
- Holtug Larssold
- Bienaime Jean Jacquesbought
- Bienaime Jean Jacquesbought
- Smith Scott Thomasbought
- Bienaime Jean Jacquesbought
- Bienaime Jean Jacquesbought
- Bienaime Jean Jacquesbought
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gary James Palmerhouse · AL06 · disclosed Nov 7, 2018 (33d later)Sell$1,001 - $15,000
- Gary James Palmerhouse · AL06 · disclosed Sep 29, 2018 (54d later)Buy$1,001 - $15,000
- Gary James Palmerhouse · AL06 · disclosed Sep 29, 2018 (79d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.